Latest News

Disease Progression of Mantle Cell Lymphoma After Ibrutinib Associated with Poor Outcome

Disease Progression of Mantle Cell Lymphoma After Ibrutinib Associated with Poor Outcome

Outcome of patients with mantle cell lymphoma who experience disease progression following ibrutinib therapy is poor.

Neoadjuvant Cetuximab Plus Chemo May Be Effective for Unresectable Squamous Cell Carcinomas

Neoadjuvant Cetuximab Plus Chemo May Be Effective for Unresectable Squamous Cell Carcinomas

Neoadjuvant cetuximab with platinum salt and fluorouracil shows good response in elderly unresectable locally advanced non-melanoma skin cancer.

Adding Cyclophosphamide to Standard Prostate Cancer Therapy Provides No Benefit

Adding Cyclophosphamide to Standard Prostate Cancer Therapy Provides No Benefit

Adding cyclophosphamide to docetaxel and prednisone for treatment of castration-resistant prostate cancer (CRPC) does not seem to provide any additional benefit.

Body Mass Index Predicts Survival in Metastatic Clear Cell Renal Cell Carcinoma

Body Mass Index Predicts Survival in Metastatic Clear Cell Renal Cell Carcinoma

Body mass index (BMI) predicts survival and overall response rates in patients with metastatic clear cell renal cell carcinoma.

Proteomic Markers Might Predict Clear Cell Renal Cell Carcinoma Survival

Proteomic Markers Might Predict Clear Cell Renal Cell Carcinoma Survival

Protein expression markers predict disease-specific survival (DSS) in clear cell renal cell carcinoma (ccRCC).

Adjuvant Sorafenib, Sunitinib for Advanced Renal Cell Carcinoma 'Should Not Be Pursued'

Adjuvant Sorafenib, Sunitinib for Advanced Renal Cell Carcinoma 'Should Not Be Pursued'

Adjuvant sorafenib and sunitinib do not improve survival for patients with locally advanced renal cell carcinoma (RCC).

International Collaboration Studies Teratoma with Malignant Transformation's 'Dismal' Outcomes

International Collaboration Studies Teratoma with Malignant Transformation's 'Dismal' Outcomes

Optimal chemotherapy remains unclear for metastatic teratoma with malignant transformation (TMT).

Neutrophil to Lymphocyte Ratio Change Associated with Survival after Targeted Therapy for mRCC

Neutrophil to Lymphocyte Ratio Change Associated with Survival after Targeted Therapy for mRCC

Baseline and changed neutrophil to lymphocyte ratio predict targeted treatment responses in metastatic renal cell carcinoma (mRCC).

MicroRNA miR-371a-3p Levels a Promising Biomarker in Testicular Germ Cell Tumors

MicroRNA miR-371a-3p Levels a Promising Biomarker in Testicular Germ Cell Tumors

Circulating microRNA miR-371a-3p levels appear to be a promising biomarker of tumor bulk in testicular germ cell tumors (GCTs).

Adjuvant Chemotherapy Improves Survival in Advanced Nonmetastatic Bladder Cancer

Adjuvant Chemotherapy Improves Survival in Advanced Nonmetastatic Bladder Cancer

Adjuvant chemotherapy is associated with better survival among patients with advanced nonmetastatic bladder cancer.

Short-Term ADT Does Not Improve Radiotherapy-Associated Survival in Prostate Cancer

Short-Term ADT Does Not Improve Radiotherapy-Associated Survival in Prostate Cancer

Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.

Dose-Escalated Radiotherapy Does Not Improve Survival in Localized Prostate Cancer

Dose-Escalated Radiotherapy Does Not Improve Survival in Localized Prostate Cancer

Dose-escalated radiotherapy does not improve overall survival compared with lower-dose radiotherapy regimens for localized prostate cancer.

Low-Dose Brachytherapy Improves Disease-Free Survival in Unfavorable-Risk Prostate Cancer

Low-Dose Brachytherapy Improves Disease-Free Survival in Unfavorable-Risk Prostate Cancer

Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.

Second-Line mFOLFOX3 Has Modest Effect in Previously Treated Biliary Tract Cancer

Second-Line mFOLFOX3 Has Modest Effect in Previously Treated Biliary Tract Cancer

Second-line mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) has modest effect in unresectable and/or metastatic biliary tract cancer.

Alisertib Safe, Active for Breast, Small-Cell Lung Cancer

Alisertib Safe, Active for Breast, Small-Cell Lung Cancer

Alisertib shows activity and is safe in patients with solid tumors, especially those with breast and small-cell lung cancer (SCLC).

SLCO2B1 Gene Polymorphisms Associated with Prostate Cancer Progression, Survival Following ADT

SLCO2B1 Gene Polymorphisms Associated with Prostate Cancer Progression, Survival Following ADT

Variants of gene SLCO2B1 associated with progression and survival among patients undergoing androgen deprivation therapy (ADT) for prostate cancer.

Cabozantinib Shows Promise Against Visceral Metastases

Cabozantinib Shows Promise Against Visceral Metastases

Compared with prednisone, cabozantinib does not improve overall survival rates for men with metastatic castration-resistant prostate cancer (mCRPC).

Docetaxel Does Not Improve Survival Following ADT for Hormone-Naïve Metastatic Prostate Cancer

Docetaxel Does Not Improve Survival Following ADT for Hormone-Naïve Metastatic Prostate Cancer

Adding docetaxel to androgen deprivation therapy (ADT) does not improve overall survival in hormone-naïve metastatic prostate cancer.

Prostate Tumor Androgen Receptor Abnormality Not Associated with Taxane Resistance

Prostate Tumor Androgen Receptor Abnormality Not Associated with Taxane Resistance

Androgen receptor V7 (AR-V7) status does not predict response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Bicalutamide Improves Survival in Advanced Nonmetastatic Hormone-Naïve Prostate Cancer

Bicalutamide Improves Survival in Advanced Nonmetastatic Hormone-Naïve Prostate Cancer

Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs